Deerfield Management

Ascertain is a collaborative venture between Northwell Health and Aegis Ventures, aimed at transforming healthcare through innovative company creation. This organization focuses on systematically developing, launching, and commercializing healthcare AI companies, utilizing a comprehensive platform that integrates medical, technological, data, and business resources. By addressing critical issues related to quality, equity, and cost in healthcare, Ascertain seeks to improve patient care and experience. The organization is dedicated to placing patient needs at the forefront of its business models and technology solutions, ultimately striving to enhance long-term health outcomes and advance the overall quality of care.

Founded in 2018, Intus Care develops a platform that connects home care providers with patients. Its application uses machine learning to predict hospital readmissions and risks, enabling efficient tracking of care providers and high-risk patient identification.

Lumeris is a company focused on transforming accountable care delivery by providing operational support, technology, and consulting services to health systems, payers, and providers. It offers a value-based care managed services platform that enhances clinical and financial outcomes through guidance and advanced risk management capabilities. By collaborating with healthcare organizations across the country, Lumeris helps them design, build, and optimize accountable care models aimed at improving quality, reducing costs, and enhancing patient and physician satisfaction. The company's innovative solutions are designed to yield better health outcomes for patients while addressing the challenges associated with chronic diseases, ultimately supporting the overarching goals of improved quality, cost efficiency, and satisfaction in the healthcare system.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Founded in 2018, Intus Care develops a platform that connects home care providers with patients. Its application uses machine learning to predict hospital readmissions and risks, enabling efficient tracking of care providers and high-risk patient identification.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

UTR Therapeutics Inc is a biotechnology company focused on developing treatments for aggressive cancers driven by the overexpression of the c-MYC gene. The company, spun out from City University of New York and Harvard Medical School, specializes in researching and developing therapeutics that target and degrade specific gene transcripts involved in tumor progression. Their primary focus is on cancers like triple negative breast cancer, medulloblastoma, and osteosarcoma, aiming to provide clinicians with treatments that directly act on cancer-causing genetic expressions.

ConcertoCare is dedicated to delivering primary and complex care to seniors and other adult patients with unmet health and social needs. The company employs a tech-enabled, value-based care model that features three distinct in-home care approaches, all supported by its proprietary population health and analytics platform. ConcertoCare's interdisciplinary teams, led by experienced professionals in home-based geriatric medicine, digital health, palliative care, and healthcare analytics, utilize clinical decision support tools to enhance patient care. This innovative model aims to lower overall healthcare costs while improving health outcomes for its patients.

DeepSight Technology enhances diagnostic medical imaging by advancing ultrasound technology. It offers proprietary sensing technology and customizable systems, integrating with industry partners to provide clinicians with deeper insights for improved patient outcomes.

Novocardia is dedicated to enhancing the delivery of cardiovascular care, aiming to support patients with heart and vascular diseases in achieving longer and healthier lives. The company operates a cardiovascular care delivery network that emphasizes improving the quality and value of care provided to patients. By fostering collaborative relationships with health plans and primary care partners, Novocardia facilitates the transition to value-based care. Its platform encompasses various capabilities, including the implementation of quality and process improvement initiatives and technology-enabled care delivery, thereby equipping cardiologists with the necessary tools to better serve their patients.

CareMax is a technology-enabled care platform focused on delivering value-based care and chronic disease management for seniors. The company operates a network of medical centers that provide a wide range of healthcare and social services. Additionally, CareMax has developed a proprietary software and services platform that offers data, analytics, and rules-based decision tools to assist physicians in their practice. This integrated approach aims to enhance the quality of care for seniors while managing their healthcare needs effectively across the United States.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Contessa, headquartered in Nashville, specializes in Home Recovery Care, a risk-based model that delivers inpatient-level care in patients' homes. Established in 2015, Contessa uses its proprietary health informatics platform to facilitate safe, affordable, and outcome-improving home care. The company offers turnkey solutions, providing upfront savings for health plans, enabling healthcare systems to reinvent their care delivery model by treating patients outside the hospital, and enhancing patient experience through better physician support.

Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.

PQ Bypass is a medical device company based in Milpitas, California, focused on transforming the treatment of long-segment peripheral artery disease through minimally-invasive endovascular solutions. Founded in 2009, the company develops and manufactures devices such as the DETOUR System, PQ Snare, PQ Crossing Device, and TORUS Stent Graft System to treat peripheral vascular disease via percutaneous surgical bypass. The executive team at PQ Bypass includes recognized leaders from the medical device industry with extensive experience in developing innovative solutions for venture-backed startups and major corporations like Medtronic, Abbott, Johnson & Johnson, Covidien, and Stryker.

NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, specializing in innovative solutions for degenerative mitral valve disease (DMR). Founded in 2007, the company has developed the NeoChord Artificial Chordae Delivery System, a proprietary device that enables mitral valve repair to be performed while the heart is still beating. This minimally invasive technique involves a small incision, significantly reducing recovery time and complications compared to traditional procedures that require larger chest incisions and stopping the heart. NeoChord's system addresses severe mitral regurgitation caused by elongated or ruptured chordae tendineae, allowing surgeons to effectively manage blood flow without the need for cardiopulmonary bypass.

Allogene Therapeutics is a clinical-stage biotech company focused on immuno-oncology, developing genetically engineered allogeneic T-cell therapies for cancer. The company builds a pipeline of off-the-shelf donor-derived CAR-T products using gene-editing and proprietary cell-manufacturing technologies to enable broader patient eligibility and scalable production. Its programs include UCART19 for relapsed or refractory acute lymphoblastic leukemia and other allogeneic CAR-T candidates targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue is primarily generated from collaborations and licensing agreements.

Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

Cureatr Inc. is a New York-based company that specializes in mobile care coordination solutions for healthcare providers. Founded in 2011, it offers a cloud-based medication management software designed to optimize patient care, particularly focusing on post-discharge medication reconciliation. The platform combines HIPAA-secure text messaging with workflow navigation tools, facilitating communication and coordination among healthcare professionals. Cureatr's software features an inbuilt dashboard that curates and analyzes patients' medication history, enabling providers to respond to real-time events and improve their interactions with patients. By streamlining these processes, Cureatr enhances the overall quality of patient care.

Ancora Innovation is a collaborative enterprise that combines the life science discovery initiatives from Vanderbilt University with Deerfield's focus on advancing drug development. The company is dedicated to accelerating the creation of early-stage therapeutics that are rooted in innovative biological research. Ancora Innovation aims to identify promising drug candidates and establish comprehensive development plans to bring these novel therapeutics to market. Additionally, it supports the growth of successful start-up companies that emerge from its research efforts, providing essential funding to facilitate transformative advancements in the pharmaceutical field.

ConcertoCare is dedicated to delivering primary and complex care to seniors and other adult patients with unmet health and social needs. The company employs a tech-enabled, value-based care model that features three distinct in-home care approaches, all supported by its proprietary population health and analytics platform. ConcertoCare's interdisciplinary teams, led by experienced professionals in home-based geriatric medicine, digital health, palliative care, and healthcare analytics, utilize clinical decision support tools to enhance patient care. This innovative model aims to lower overall healthcare costs while improving health outcomes for its patients.

Neos Therapeutics, Inc. is a pharmaceutical company based in Grand Prairie, Texas, focused on the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD). Utilizing its proprietary drug delivery technology platform, Neos produces extended-release medications in various forms, including orally disintegrating tablets and liquid suspensions. Its product lineup features Adzenys XR-ODT and Adzenys ER, both amphetamine-based treatments, and Cotempla XR-ODT, a methylphenidate formulation, all designed to address ADHD symptoms. Additionally, the company markets generic Tussionex, a hydrocodone and chlorpheniramine polistirex oral suspension for cough relief. Neos is also developing NT0502, a clinical-stage candidate aimed at treating chronic sialorrhea associated with certain neurological conditions. The company operates primarily in the United States and is committed to creating high-quality products that meet significant medical needs.

Lumeris is a company focused on transforming accountable care delivery by providing operational support, technology, and consulting services to health systems, payers, and providers. It offers a value-based care managed services platform that enhances clinical and financial outcomes through guidance and advanced risk management capabilities. By collaborating with healthcare organizations across the country, Lumeris helps them design, build, and optimize accountable care models aimed at improving quality, reducing costs, and enhancing patient and physician satisfaction. The company's innovative solutions are designed to yield better health outcomes for patients while addressing the challenges associated with chronic diseases, ultimately supporting the overarching goals of improved quality, cost efficiency, and satisfaction in the healthcare system.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Cureatr Inc. is a New York-based company that specializes in mobile care coordination solutions for healthcare providers. Founded in 2011, it offers a cloud-based medication management software designed to optimize patient care, particularly focusing on post-discharge medication reconciliation. The platform combines HIPAA-secure text messaging with workflow navigation tools, facilitating communication and coordination among healthcare professionals. Cureatr's software features an inbuilt dashboard that curates and analyzes patients' medication history, enabling providers to respond to real-time events and improve their interactions with patients. By streamlining these processes, Cureatr enhances the overall quality of patient care.

NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, specializing in innovative solutions for degenerative mitral valve disease (DMR). Founded in 2007, the company has developed the NeoChord Artificial Chordae Delivery System, a proprietary device that enables mitral valve repair to be performed while the heart is still beating. This minimally invasive technique involves a small incision, significantly reducing recovery time and complications compared to traditional procedures that require larger chest incisions and stopping the heart. NeoChord's system addresses severe mitral regurgitation caused by elongated or ruptured chordae tendineae, allowing surgeons to effectively manage blood flow without the need for cardiopulmonary bypass.

Vital Access Corporation is a development stage company based in Salt Lake City, Utah, founded in 2006. The company specializes in the development of surgical and interventional technologies aimed at improving vascular access for patients and their caregivers. Its product offerings include vascular access ports, tissue management apparatus, and various systems designed to create and maintain vascular access. Through its innovative technologies, Vital Access seeks to enhance the treatment capabilities of physicians, ultimately aiming to improve patient care.

Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. Established in 1995, the company markets four FDA-approved products: Gralise for managing postherpetic neuralgia, Cambia for treating migraines, Zipsor for relieving mild to moderate acute pain, and Lazanda for managing breakthrough cancer pain.

Epion Health, Inc. is a developer of a patient engagement platform that offers a range of mobile health applications and content through a cloud-based solution. Founded in 2011 and headquartered in Roseland, New Jersey, the company enables patients to access health-related information on their smartphones or mobile devices, helping them learn about their health and prepare for medical visits. Additionally, the platform provides physicians with access to essential health information, including pre-loaded medical applications such as drug references, dosage calculators, and health assessments. By facilitating communication between patients and healthcare providers, Epion Health aims to enhance patient care and improve overall efficiency in the healthcare continuum.

OMNIlife science, Inc. specializes in the design, manufacture, and distribution of orthopedic devices, focusing on joint replacement solutions. Founded in 1999 and headquartered in East Taunton, Massachusetts, the company offers a range of products, including orthopedic implants for knees and hips, as well as advanced robotic navigation technology known as OMNINAV, which enhances the precision of total knee surgeries tailored to individual patients. The company serves a diverse international market, including regions such as South Africa, Switzerland, Turkey, and several European countries, distributing its products through various distributors. OMNIlife science operates as a subsidiary of Orthopaedic Synergy, Inc.

Wellfount Corp., established in 2006 and headquartered in Indianapolis, Indiana, specializes in providing pharmacy services to nursing facilities. The company offers a range of services including utilization and compliance reviews, multi-dose and compliance packaging, daily deliveries, intravenous therapy, and customized invoicing. Wellfount also provides EHR application integration and medical record services, along with medications and consulting services. Through its innovative technologies, the company aims to improve patient care quality and reduce costs by streamlining medication management processes in long-term care facilities.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for orphan diseases, particularly those involving involuntary movement disorders. The company’s pipeline features product candidates aimed at addressing significant unmet medical needs, including hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Auspex Pharmaceuticals specializes in creating deuterated analogs of clinically-validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory disease and inflammation. Through its focused approach, the company seeks to provide effective treatment options for patients suffering from these challenging conditions.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing proprietary therapeutics for chronic diseases. The company utilizes its innovative ProNeura technology, a long-term drug delivery platform, to create products that maintain stable blood levels of medication over extended periods. Titan's principal product, Probuphine, is the first slow-release implant formulation of buprenorphine, designed for the outpatient treatment of opioid dependence. This implant allows for consistent medication delivery for up to six months, enhancing patient compliance and reducing the risk of misuse associated with traditional sublingual formulations. Additionally, Titan is developing ProNeura-Ropinirole, an implant for treating Parkinson’s disease, and a triiodothyronine implant for hypothyroidism. Established in 1992, Titan is committed to addressing serious medical disorders through its advanced drug delivery solutions.

Exelixis is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for cancer. Its primary product, cabozantinib, is marketed as Cometriq for metastatic medullary thyroid cancer and Cabometyx for kidney and liver cancers. Exelixis also offers Cotellic in collaboration with Roche for melanoma treatment.

NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.

Exelixis is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for cancer. Its primary product, cabozantinib, is marketed as Cometriq for metastatic medullary thyroid cancer and Cabometyx for kidney and liver cancers. Exelixis also offers Cotellic in collaboration with Roche for melanoma treatment.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.